RA
SLNO

Royce & Associates’s Soleno Therapeutics SLNO Stock Holding History

Royce & Associates’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-129,043
Closed -$5.97M – 805
2025
Q4 		$5.97M Buy
129,043
+98,056
+316% +$5.38M 0.06% 430
2025
Q3 		$2.09M Sell
30,987
-69,711
-69% -$5.17M 0.02% 587
2025
Q2 		$8.44M Buy
100,698
+96,698
+2,417% +$7.24M 0.09% 335
2025
Q1 		$286K Buy
+4,000
New +$195K ﹤0.01% 759

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Royce & Associates's SLNO Position: Q1 2026 in Review

Royce & Associates sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 129,043 shares — an estimated $5.97M sold.

Royce & Associates first reported a position in SLNO in Q1 2025 and held it in 4 quarters. The position peaked at $8.44M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Royce & Associates reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Royce & Associates sold 129,043 Soleno Therapeutics shares in Q1 2026, an estimated $5.97M.
  • Royce & Associates first reported a position in Soleno Therapeutics in Q1 2025 and held it in 4 quarters.
  • Royce & Associates's Soleno Therapeutics position peaked at $8.44M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.